
Hinge Health, Inc.
HNGEHinge Health, Inc. is a healthcare company specializing in digital musculoskeletal (MSK) health solutions. It develops and provides wearable sensors, digital programs, and remote physical therapy to help manage and treat chronic pain and musculoskeletal conditions. Founded to improve access to personalized care, Hinge Health aims to reduce pain and improve functional outcomes through innovative technology-enabled interventions.
Company News
Insight Holdings Group, an early backer of Hinge Health, sold 426,000 shares worth $38.4 million at $90.21 per share following the stock's 101% one-year appreciation. The sale was executed through a routine options exercise and immediate liquidation, not a complete exit, as the firm retains substantial derivative securities. Hinge Health continue...
The global digital health for musculoskeletal care market is projected to grow from $3.8 billion in 2025 to $10.9 billion by 2032, with a CAGR of 16.4%. Growth is driven by rising MSK disorder prevalence, wearable device adoption, AI-powered remote physiotherapy, telehealth expansion, and increasing insurance coverage for digital MSK solutions.
Hinge Health's co-founder Gabriel Mecklenburg sold 50,000 Class A shares worth $3.28 million on June 5, 2026. However, the article suggests this is not a major red flag as Mecklenburg retains 2.97 million shares in Class B holdings. The company shows strong fundamentals with 47% year-over-year sales growth, expanding margins (85% gross margin), a...
Smart ring maker Oura Health is preparing for an IPO that could serve as a key test for whether public markets are ready to support consumer-facing health technology companies. Unlike earlier wearable makers, Oura relies on a subscription model for health insights rather than just device sales. The company's debut comes as the digital health sect...
Hinge Health, a mid-cap healthcare stock focused on virtual musculoskeletal therapy, is gaining traction with insurers as a cost-reduction solution amid rising U.S. healthcare costs. The company reported 46% revenue growth and 23% EPS growth, exceeding estimates, with a study showing 56% lower spinal fusion surgery rates among its users. However,...



